Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Slow vs Standard Semaglutide Titration in T2DM
NCT04447859Phase 3Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Feb 2020
- Primary completion
- May 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Tel Aviv Sourasky Medical Center. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04447859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447859.